We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise
Read MoreHide Full Article
Acorda Therapeutics, Inc.’s shares gained almost 7% after the U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld four patents of its key growth driver, Ampyra.
Acorda holds five Orange Book listed patents for Ampyra that run until 2027.
The four U.S. patents upheld include 8,663,685 (the ‘685 patent), 8,440,703 (the ‘703 patent), 8,354,437 (the ‘437 patent) and 8,007,826 (the ‘826 patent), which are set to expire in 2025, 2025, 2026 and 2027, respectively.
Meanwhile, inter partes review (IPR) petitions challenging U.S. ’938 patent that also pertain to Ampyra have been filed in the U.S. District Court for the District of Delaware. The Court has completed the trial of the case but has not yet announced its decision.
We note that Acorda is facing patent challenges for Ampyra is the U.S. A total of ten generic drug manufacturers have submitted abbreviated new drug applications (ANDA), with the FDA seeking marketing approval for generic versions of Amypra. In 2015 and 2016, Acorda reached settlement agreements with six of the generic companies including Allergan plc . The patent infringement case against Mylan N.V. , however, is still proceeding in Delaware alongside cases against other ANDA filers.
Ampyra is Acorda’s flagship product, which is currently approved in the U.S. for the improvement of walking in multiple sclerosis patients. It is available outside the U.S. under the trade name Fampyra. The drug registered sales of $492.8 million in 2016, reflecting an increase of 12.8%. Acorda has a licensing agreement with Biogen (BIIB - Free Report) for Fampyra in markets outside the U.S.
Currently, Acorda is working on expanding Ampyra’s label into additional indications.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise
Acorda Therapeutics, Inc.’s shares gained almost 7% after the U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld four patents of its key growth driver, Ampyra.
Acorda holds five Orange Book listed patents for Ampyra that run until 2027.
The four U.S. patents upheld include 8,663,685 (the ‘685 patent), 8,440,703 (the ‘703 patent), 8,354,437 (the ‘437 patent) and 8,007,826 (the ‘826 patent), which are set to expire in 2025, 2025, 2026 and 2027, respectively.
Meanwhile, inter partes review (IPR) petitions challenging U.S. ’938 patent that also pertain to Ampyra have been filed in the U.S. District Court for the District of Delaware. The Court has completed the trial of the case but has not yet announced its decision.
We note that Acorda is facing patent challenges for Ampyra is the U.S. A total of ten generic drug manufacturers have submitted abbreviated new drug applications (ANDA), with the FDA seeking marketing approval for generic versions of Amypra. In 2015 and 2016, Acorda reached settlement agreements with six of the generic companies including Allergan plc . The patent infringement case against Mylan N.V. , however, is still proceeding in Delaware alongside cases against other ANDA filers.
Ampyra is Acorda’s flagship product, which is currently approved in the U.S. for the improvement of walking in multiple sclerosis patients. It is available outside the U.S. under the trade name Fampyra. The drug registered sales of $492.8 million in 2016, reflecting an increase of 12.8%. Acorda has a licensing agreement with Biogen (BIIB - Free Report) for Fampyra in markets outside the U.S.
Currently, Acorda is working on expanding Ampyra’s label into additional indications.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>